Table 3.
Baseline characteristics of the early RA LEEDS population studied.
| mtx | Remission (n = 29) | No remission (n = 45) | p-value |
|---|---|---|---|
| Age* (years) | 59 (47–66) | 50 (41–62) | 0.408 |
| Sex (M/F) | 7/22 | 11/34 | 0.601 |
| Smoking | 15/14 | 16/28 | 0.231 |
| Symptoms (m)* | 6.2 [4.8–12.9] | 6 (3.7–13.6) | 0.829 |
| RF (+/–) | 15/14 | 22/22 | 0.538 |
| ACPA (+/–) | 20/9 | 23/22 | 0.129 |
| TJC* | 2 (1–10) | 10 (4–15) | 0.001 |
| SJC* | 3 (0–9) | 4 (1–8) | 0.587 |
| CRP* | 8 (<5–18.5) | 12 (<5–27) | 0.077 |
| DAS28* | 4.10 (2.24–4.80) | 4.50 (3.40–5.6) | 0.020 |
| SOCS1*† | 0.41 (0.21–0.58) | 0.26 (0.08–0.47) | 0.036 |
| RITUXIMAB | No response (n= 16) | Mod/Good response (n= 49) | p-value |
| Age* (years) | 48 (46–64) | 57 (48–64) | 0.598 |
| Sex (M/F) | 2/14 | 9/40 | 0.443 |
| symptoms (m)* | 70 (25–94) | 102 (36–204) | 0.244 |
| RF (+/–) | 16/0 | 42/7 | 0.123 |
| ACPA (+/–) | 15/1 | 46/3 | 0.687 |
| TJC* | 15 (9–24) | 16 (10–23) | 0.703 |
| SJC* | 7.5 (3–17) | 8 (5–11) | 0.328 |
| CRP* | 46 (>5–123) | 12.5 (>5–23) | 0.192 |
| DAS28* | 5.76 (4.6–7.2) | 5.67 (4.7–6.2) | 0.732 |
| SOCS1*† | 0.640 (0.273–0.775) | 0.880 (0.680–1.405) | 0.035 |
M, male; F, female; RF, rheumatoid factor; ACPA, anti-citrullinated proteins antibodies; TJC, tender joint count; SJC, swollen joint count; CRP, C-reactive protein; DAS28, disease activity score calculated with the 28 joint count; SOCS1, suppressor of cytokine signaling;
†
(normalized quantity, using GADPDH)
*
median and (interquartile range). Values in bold are statistical significance.